Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

Liver cancer remains a global health challenge, with an estimated incidence of> 1 million
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its
mortality is third among all solid tumors, behind carcinomas of the lung and the colon …

Local and regional therapies are recommended for patients with hepatocellular carcinoma
(HCC) in very early (Barcelona Clinic Liver Cancer [BCLC] 0), early (BCLC A), and …

Ablative treatments currently represent the first-line option for the treatment of early stage
unresectable hepatocellular carcinoma (HCC). Furthermore, they are effective as …

Background Hepatocellular carcinoma (primary liver cancer) is classified in many ways. The
Barcelona Clinic Liver Cancer (BCLC) group staging classifies the cancer based on patient's …

肝癌发生发展机制的研究进展及其治疗现状 Page 1 第27 卷第7 期 2018 年7 月 中国普通外科
杂志 Chinese Journal of General Surgery Vol.27 No.7 Jul. 2018 © 版权归中国普通外科杂志 …

Background Percutaneous ablation has quickly arisen as one of the important alternative
treatments for hepatocellular carcinoma (HCC). We aimed to compare the therapeutic effects …

The increasing set of liver-directed therapies (LDT) have become an integral part of
hepatocellular carcinoma (HCC) treatment. These range from percutaneous ablative …